Small Seed Grants Keep Early-Career Researchers Going
A conversation between Binaytara President and Cofounder Binay Shah, MD, MHA, and Clinical Leader Executive Editor Abby Proch

The stretch between training grants and a first major independent award is precarious. Amid recent cuts to public research funding, that gap has grown harder to cross, and promising work by early-career researchers is in jeopardy.
Binay Shah, MD, MHA, knows all about this. Shah is the president and cofounder of Binaytara, a global oncology nonprofit working to minimize cancer health disparities, in part, by funding early-career cancer research. This fall, the organization awarded funding to seven early-career investigators whose projects range from preclinical lab work to in-human studies.
In this Q&A, Shah discusses what researchers are telling him about today’s funding environment and how (and where) seed funding can make the biggest difference for a clinical study.
Clinical Leader: How has the current state of public research funding affected early-career clinical investigators? Specifically, what are you hearing from the researchers who apply for these awards?
Binay Shah, MD, MHA: I meet hundreds of physicians and researchers every month at conferences, and funding cuts come up in almost every conversation. The concern is across the board: Researchers at large academic centers and at smaller programs describe the same uncertainty. Early-career investigators feel it most: Fewer awards and less predictable funding decisions mean promising ideas stall before they can be tested. For our 2026 National Summit on Hematologic Cancers, more than 700 researchers from 18 countries submitted abstracts.
That number tells me the ideas are there, but the financial backing is not. A traditional grant can take months, with limited feedback. And funding is harder to find in places such as South America; one of our recent award winners, from Peru, received $50,000. At our conferences, experts question applicants on stage, and we announce winners before the meeting ends, so researchers leave with funding or with advice for their next application.
Early-career investigators can experience a funding gap between training grants and their first major independent award. Where in that gap does a $25,000 or $50,000 award make the most difference, and what can it help accomplish for a clinical study?
Binaytara’s research awards are seed grants for pilot projects, and those pilot data make an investigator competitive for their first major independent grant. In 2026 alone, we have awarded $425,000 to early-career investigators. As an example, Dr. Samuel Urrutia at Washington University in St. Louis is using his award to bring whole-genome sequencing for acute myeloid leukemia to local labs in Paraguay and Peru, with the goal of returning results to patients in five to 10 days instead of up to two months. He sees it as the foundation of an international genomics consortium for leukemias in the region.
What role should nonprofits, foundations, and industry play in sustaining early-career research, and what are the risks of the field relying more heavily on private money?
Private funders work best as bridges and catalysts: They take early risks, fill gaps, and back questions that public funding overlooks. But they cannot replace public funding. If the field leans too heavily on private money, research priorities risk drifting toward what is commercially attractive rather than what is scientifically needed.
This year’s awardees’ research ranges from lab-based preclinical work to in-human studies. How do you and the judges weigh projects at different stages, and what signals of near-term clinical impact do you look for?
We judge each project against what is realistic for its stage. Every proposal is assessed on the same core criteria: Is the science sound and the methodology strong? Is the project feasible, with good mentorship and institutional support, and could the findings advance the field?
A preclinical project should have a clear path to a clinical question, and an in-human study should be able to enroll patients and finish on time. We also look for evidence that the award will lead to the next step in the investigator’s research.
This year at our National Summit on Hematologic Cancers in Nashville, nine finalists took part in our Impact Pitch competition, in which each had 7 minutes to pitch and 7 minutes to answer questions from four senior judges. When the decision happens in front of peers, the strongest idea in the room wins. Among the winners, Dr. Federico Mario Aletti at MD Anderson Cancer Center is doing the preclinical safety work needed to take a new CAR T-cell therapy for T-cell lymphoma into clinical trials, while Dr. Melanie Castro Mollo at Peru’s Instituto Nacional de Enfermedades Neoplásicas is planning a trial of lower-dose chemotherapy plus venetoclax that aims to cut early deaths among adults with Ph-chromosome-negative acute lymphoblastic leukemia from about 30% to 10%.
Beyond funding, how does Binaytara stay involved with awardees after the summit, including mentorship, visibility, and connections to trial sites or sponsors?
An award is the start of a relationship, not a one-time transaction. Awardees keep us updated through regular progress reports, and they come back to share their results at a future Binaytara conference. Many go on to serve as faculty at our conferences, where they gain visibility and build connections across the field.
What would you ask of biopharma sponsors, CROs, and research site leaders who want to see a healthy pipeline of clinical investigators? What specific steps could they take to support early-career researchers?
They should invest in early-career investigators the way they invest in a drug pipeline. Sponsors can open their investigator-initiated trial programs to junior researchers. They can also bring early-career researchers into industry studies as co-investigators alongside experienced principal investigators. CROs and site leaders can share infrastructure, regulatory help, and coordinator support. But most of all, they can protect research time. Too many talented clinicians, especially in academia, leave research simply because they never have the time to do it.
About The Expert:
Binay Shah, MD, MHA, is a hematologist/oncologist and the president and cofounder of Binaytara, a global oncology nonprofit working to minimize cancer health disparities. Born and trained in Nepal before completing residency and fellowship in the United States, he leads an organization that runs hematology and oncology conferences accredited for continuing medical education across the U.S., funds early-career cancer research through its live Impact Pitch competition, and provides cancer screening and care in Janakpur, Nepal, where he is building a comprehensive cancer hospital. His commentary has appeared in STAT News, KFF Health News, and The Seattle Times.